Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
EnteroMedics registered for a follow-on offering that could bring in as much as $15 million for its Maestro obesity device.
St. Paul, Minn.-based EnteroMedics won FDA approval for the Maestro device in January 2015, following a mixed vote last year after the device failed to meet its efficacy endpoint in a clinical trial. It’s designed to use what EnteroMedics calls “vBloc therapy,” in which electrical pulses are used to block intra-abdominal vagus nerve signaling between the brain and stomach using a pacemaker-like device. Read more
Johnson & Johnson’s Ethicon subsidiary said today that it’s dropping $3.2 million on a research program on the effects of early surgical intervention on obesity and Type II diabetes.
Cincinnati-based Ethicon said its “Time to Act on Obesity” program involves more than 20 clinical trials enrolling some 2,000 patients and investigator-initiated studies in 5 countries. Read more
The American Heart Association/American Stroke Association said today that it updated its treatment guidelines for patients suffering from ischemic stroke to include endovascular treatments.
The decision supports the use of stent retrieval, and other thrombectomy devices, used to remove clots in patients who have obstructions in the large arteries supplying blood to the brain according to a new focused update published in the American Heart Association journal Stroke. Read more